Home / Themes / Biotech '25: Oncology & Immunotherapy
Last updated
Theme thesis · 2/5 sections · Tickers 0 with notes · 12 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
This theme focuses on biotechnology companies developing innovative cancer treatments that harness the body's immune system. It encompasses advancements in immu
This theme focuses on biotechnology companies developing innovative cancer treatments that harness the body's immune system. It encompasses advancements in immunotherapies, personalized medicine, and combination approaches to target and eliminate cancer cells more effectively, aiming for improved patient outcomes and long-term disease control, despite rising costs and regulatory scrutiny.
The oncology and immunotherapy landscape is characterized by continuous innovation and the proliferation of advanced treatment modalities. This includes the increasing criticality of combination therapies, pairing immune checkpoint inhibitors with other treatments, and the emergence of novel approaches like cellular therapies, antibody-drug conjugates, bispecific antibodies, and radiopharmaceuticals, which are establishing new standards of care across various cancer types.
There is robust and sustained investment in oncology and immunotherapy R&D, reflected in expanding specialized clinical roles and a high volume of new clinical trials. In the first half of 2026, over 40% of venture capital funding in biotech was directed towards cancer and immunology drug development, underscoring the significant commercial potential recognized by investors.
The market is experiencing growing adoption and expanding patient eligibility for immunotherapy treatments, leading to increased healthcare spending on prescription drugs. Global spending on oncology drugs is projected to rise significantly, from $252 billion in 2024 to $441 billion by 2029, with a substantial increase in patients eligible for and benefiting from these therapies.
The theme faces significant risks from increasing regulatory scrutiny and persistently high clinical trial failure rates, particularly in oncology. While immuno-oncology shows better success rates than other oncology approaches, the overall likelihood of approval from Phase I remains challenging, with Phase II being a major hurdle, and oncology trials often having longer and more costly development timelines.
Escalating drug pricing and growing pressure from policymakers and payers pose a substantial risk to the theme's profitability and market access. Oncology drugs are among the most expensive, and the Inflation Reduction Act (IRA) in the U.S. is enabling Medicare price negotiations, leading to significant discounts and potential reimbursement challenges for providers, which could impact patient access and the viability of community oncology practices.
The intense and evolving competitive landscape within oncology and immunotherapy necessitates continuous innovation and differentiation. With numerous new approvals and emerging modalities, companies must demonstrate superior efficacy and safety to gain market share, as less differentiated products face the risk of being supplanted by newer, more effective treatments.
patient experiences with immunotherapy, clinical trial discussions, side effects, treatment efficacy, emotional support
caregiver perspectives on immunotherapy, treatment decisions, managing side effects, family support
specific discussions on melanoma immunotherapy, drug experiences (e.g., Keytruda, Opdivo), recurrence, side effect management
general patient discussions, treatment comparisons, practical advice, community support
American Cancer Society community forums, broad cancer discussions, treatment options, research updates
Not in registryaccess=api
Metric/field HCPIDRUG
Cadence quarterly
Why it matters Indicates overall spending on prescription drugs, directly impacting revenue potential for biotech firms in the oncology and immunotherapy space.
Signal to watch Increasing trend suggests a growing market and higher revenue potential for pharmaceutical products.
Confidence: high
Not in registryaccess=api
Metric/field RDPCE
Cadence quarterly
Why it matters Reflects the investment appetite of the private sector in innovation, which is crucial for R&D-heavy biotech companies focused on new therapies.
Signal to watch Sustained or increasing R&D spending indicates continued innovation and pipeline development within the broader economy.
Confidence: high
Not in registryaccess=api
Metric/field GS10
Cadence daily
Why it matters Serves as a benchmark for long-term borrowing costs, impacting financing for R&D, clinical trials, and potential M&A activities for biotech companies.
Signal to watch Lower yields reduce borrowing costs, potentially encouraging investment and M&A; higher yields increase the cost of capital.
Confidence: high
Not in registryaccess=api
Metric/field CUUR0000SAM
Cadence monthly
Why it matters Measures inflation specifically within the medical care sector, impacting operational costs for biotech firms and potential pricing power for their products.
Signal to watch Moderate inflation suggests a stable pricing environment; high inflation could pressure margins or lead to increased scrutiny on drug pricing.
Confidence: high
Not in registryaccess=api
Metric/field GDPC1
Cadence quarterly
Why it matters General economic health influences overall healthcare spending, patient access to treatments, and government budgets allocated to healthcare and research.
Signal to watch Strong GDP growth typically correlates with higher healthcare spending and a more favorable investment climate for innovative therapies.
Confidence: medium
Not in registry
Metric/field Number of new studies registered with 'Oncology' OR 'Immunotherapy' in 'Condition or disease' or 'Intervention/treatment' fields (status: 'Recruiting' or 'Not yet recruiting')
Cadence daily
Why it matters Indicates the pace of new research and development in the core theme areas, signaling future pipeline potential and scientific activity.
Signal to watch An increasing number of new trials suggests a robust and expanding R&D landscape, pointing to future innovation.
Confidence: high
Not in registry
Metric/field Number of new drug approvals (NDA/BLA) for oncology or immunotherapy indications (search 'Oncology' or 'Immunotherapy' in 'Therapeutic Area' or 'Indication')
Cadence event_driven
Why it matters Directly measures regulatory success and market entry for new treatments, which is crucial for revenue generation and validating R&D efforts.
Signal to watch A higher number of approvals indicates a favorable regulatory environment and successful progression of new therapies to market.
Confidence: high
Not in registry
Metric/field Search interest index for 'cancer immunotherapy' (worldwide or US)
Cadence daily
Why it matters Reflects public and patient interest in the theme's core technologies, potentially indicating future demand, awareness, and engagement with new treatments.
Signal to watch Rising search interest suggests increasing public awareness and potential future adoption or discussion around these therapies.
Confidence: medium
Not in registry
Metric/field Number of new grants awarded with 'oncology' or 'immunotherapy' in project title/abstract
Cadence monthly
Why it matters Indicates government funding and scientific focus on key research areas, often serving as a precursor to future drug development and innovation.
Signal to watch Increased grant funding suggests sustained government support and scientific momentum in the field of oncology and immunotherapy.
Confidence: high
Not in registry
Metric/field Number of new patents granted in IPC classes related to oncology/immunotherapy (e.g., A61K39/00 for vaccines/immunostimulants, A61P35/00 for antineoplastic agents)
Cadence weekly
Why it matters Reflects innovation and intellectual property protection in the biotech space, which is crucial for competitive advantage and future market exclusivity.
Signal to watch A growing number of relevant patents indicates a healthy pace of innovation and potential for new, protected therapies.
Confidence: high
Matchediqvia_prescription_rx_data · access=file · map_only
Metric/field Weekly New-to-Brand Prescriptions (NBRx) for key oncology and immunotherapy drug classes (e.g., PD-1 inhibitors, CAR-T therapies)
Cadence irregular
Why it matters Provides real-time insight into the adoption and market penetration of new and existing drugs, directly impacting revenue and market share for theme members.
Signal to watch Increasing NBRx indicates strong market uptake and favorable physician prescribing trends for relevant therapies.
Confidence: high
Not in registry
Metric/field Probability of Success (PoS) changes for Phase 2 and Phase 3 oncology/immunotherapy assets
Cadence monthly
Why it matters Quantifies the likelihood of a drug successfully completing clinical trials and gaining regulatory approval, a key value driver for biotech companies.
Signal to watch Upward revisions in PoS for late-stage assets signal increased confidence in future approvals and significant market potential.
Confidence: high
Not in registry
Metric/field Physician adoption intent and prescribing patterns for recently approved or emerging oncology/immunotherapy drugs
Cadence monthly
Why it matters Gauges the willingness of healthcare providers to prescribe new therapies, directly influencing market penetration and sales volumes.
Signal to watch High or increasing adoption intent suggests strong market acceptance and future sales growth for specific treatments.
Confidence: high
Not in registry
Metric/field Changes in formulary coverage status (e.g., preferred, restricted, non-covered) for key oncology/immunotherapy drugs across major US payers
Cadence monthly
Why it matters Formulary placement dictates patient access and reimbursement, critically impacting drug sales volumes and market reach.
Signal to watch Improved formulary coverage (e.g., moving to preferred status) indicates broader patient access and higher sales potential.
Confidence: high
Matchedclarivate_scientific_publications_citations · access=file · map_only
Metric/field Volume and sentiment of publications, presentations, and social media mentions by top oncology/immunotherapy KOLs regarding emerging therapies or specific companies
Cadence irregular
Why it matters KOL influence can significantly impact the perception, adoption, and ultimate success of new drugs and technologies in the medical community.
Signal to watch Positive sentiment and increased activity from KOLs regarding a specific therapy or company can signal strong future prospects and market acceptance.
Confidence: medium
3 stories tagged to this theme — Narrative Radar (NewsAPI.ai) and TimBot picks.
